ModifiedPremera BluecrossPolicy N/A

Intravenous Iron Replacement Products

Medical necessity and coverage criteria for intravenous iron replacement therapies for iron deficiency anemia, including product-specific indications, age limits, documentation, coding, and approval durations; applies to providers under Premera Bluecross medical benefit.

Policy Summary

PayerPremera Bluecross

PolicyIntravenous Iron Replacement Products

Policy CodePolicy N/A

Change TypeRevised appendix thresholdsclarified prescribing and added product coverage

Effective DateJun 1, 2026

Next Review DateMay 1, 2026

Key ActionObtain prior authorization and submit office visit notes documenting diagnosis, history, exam and medication history to demonstrate medical necessity.

SourceLink

POLICY UPDATE CHANGES

Updated Appendix laboratory values associated with inadequate response to iron therapy in iron deficiency anemia with chronic kidney disease to align with KDIGO 2026 guideline and added a GFR stages table.

Clarified that the medications listed are subject to the product's FDA dosage and administration prescribing information and that non-formulary exception authorizations may be approved up to 12 months.

Added coverage criteria for Injectafer (ferric carboxymaltose) for treatment of certain adults with heart failure.

up to 3 monthsinitial authorization duration

up to 6 monthsre-authorization duration

18+adult age threshold

TSAT ≤30% & ferritin ≤500

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

CKD G5 HD initiation

90-day noticeprovider notification period

Coverage and Medical Necessity Criteria

Inadequate response — iron deficiency anemia without CKD

Laboratory values associated with an inadequate response to iron therapy — iron deficiency anemia without chronic kidney disease (CKD).

Children ≥ 6 months to < 5 years: Ferritin < 15 ng/mL, and/or Hemoglobin < 11 g/dL

Children ≥ 5 to < 12 years: Ferritin < 15 ng/mL, and/or Hemoglobin < 11.5 g/dL

Males ≥ 12 to < 15 years: Ferritin < 15 ng/mL, and/or Hemoglobin < 12 g/dL

Males ≥ 15 years: Ferritin < 15 ng/mL, and/or Hemoglobin < 13 g/dL

Females ≥ 12 years (Nonpregnant): Ferritin < 15 ng/mL, and/or Hemoglobin < 12 g/dL

Females ≥ 12 years (Pregnant): Ferritin < 15 ng/mL, and/or Hemoglobin < 11 g/dL

Billing and Code List

HCPCS codesHCPCS

J1437	Injection, ferric derisomaltose (use to report: Monoferric), 10 mg
J1439	Injection, ferric carboxymaltose (use to report: Injectafer), 1 mg
Q0138	Injection, ferumoxytol, for treatment of iron deficiency anemia (use to report: Feraheme), 1 mg (non-ESRD use)
Q0139	Injection, ferumoxytol, for treatment of iron deficiency anemia (use to report: Feraheme), 1 mg (for ESRD on dialysis)

Policy-associated HCPCS codesHCPCS

J1437	HCPCS code added to policy (historical addition)
J1439	HCPCS code added to policy (historical addition)
Q0138	HCPCS code added to policy (historical addition)
Q0139	HCPCS code added to policy (historical addition)

CKD G5 HD iron initiation threshold (TSAT and ferritin values)

CKD G5 on hemodialysis (G5HD)TSAT ≤ 30% AND ferritin ≤ 500 ng/mL

Applies toAdults and children regardless of ESA or HIF-PHI treatment

PurposeThresholds indicate suggestion to initiate iron therapy in CKD G5 patients receiving hemodialysis

Non-dialysis / peritoneal dialysis iron initiation thresholds (ferritin and TSAT combinations)

Option AFerritin < 100 ng/mL AND TSAT < 40%

Option BFerritin ≥ 100 ng/mL and < 300 ng/mL AND TSAT < 25%

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Prior authorization and approval durations

Prior authorization is required for all drugs listed in this policy. Initial authorizations may be approved for up to 3 months. Re-authorizations may be approved for up to 6 months in duration when the drug-specific coverage criteria are met and chart notes document medical necessity, including a documented positive clinical response (e.g., hemoglobin increase ≥ 1 g/dL from baseline) and laboratory results demonstrating need for additional therapy. Non-formulary exception review authorizations for all drugs listed in this policy may be approved up to 12 months per the payer's formulary exception process.

Initial authorization: up to 3 months
Re-authorization: up to 6 months when criteria and documentation met
Non-formulary exception approvals: may be approved up to 12 months

Billing Rule

Clinical Background

Anemia reflects a reduced red blood cell mass or hemoglobin concentration and can result from multiple causes including iron deficiency, chronic kidney disease (CKD), gastrointestinal blood loss, and other medical conditions. Intravenous iron is used to rapidly replete iron stores when oral iron is not tolerated, ineffective, or when clinical circumstances (for example, CKD or ongoing blood loss) warrant parenteral therapy. IV iron formulations differ by core iron and carbohydrate shell, which affect dosing, administration, and safety; contemporary agents generally offer improved tolerability compared with older preparations. Clinical decisions about IV iron selection should consider the indication (including CKD stage and dialysis status), urgency of repletion, prior response or intolerance to oral iron, and product labeling.

Definitions and Clinical Terms

Definition — Iron deficiency anemia (IDA)

DefinitionIron deficiency anemia (IDA): anemia due to insufficient iron to make hemoglobin, often presenting with fatigue, weakness, dizziness, and shortness of breath

Clinical contextCommon causes include nutritional deficiencies, chronic kidney disease, gastrointestinal disease, and infectious diseases

Treatment roleIntravenous iron replacement is used to rapidly replace iron stores when oral iron is not tolerated or ineffective

IV iron formulations overview

OverviewIntravenous iron formulations consist of an elemental iron core bound by carbohydrate moieties; differences in approved indications, dosing convenience, and safety profile guide product choice

Newer agentsCarboxymaltose, ferumoxytol, and derisomaltose have newer carbohydrate moieties that may be less immunogenic with lower hypersensitivity risk

Policy Summary

PayerPremera Bluecross

PolicyIntravenous Iron Replacement Products

Policy CodePolicy N/A

Change TypeRevised appendix thresholdsclarified prescribing and added product coverage

Effective DateJun 1, 2026

Next Review DateMay 1, 2026

Key ActionObtain prior authorization and submit office visit notes documenting diagnosis, history, exam and medication history to demonstrate medical necessity.

SourceLink

On This Page

Applies toIndividuals not receiving dialysis or CKD G5 on peritoneal dialysis (adults and children; includes KTRs)

Ferritin and TSAT thresholds cross-reference — see coverage criteria

Reference for exact numeric thresholdsSee Coverage Criteria module: CKD-specific ferritin and TSAT thresholds by dialysis status and age (CKD G5 HD: TSAT ≤ 30% & ferritin ≤ 500 ng/mL; Non-dialysis/peritoneal dialysis: ferritin <100 & TSAT <40 OR ferritin 100–299 & TSAT <25)

Non-CKD inadequate-response valuesAge-based ferritin and hemoglobin thresholds for inadequate response (see Appendix) — e.g., ferritin <15 ng/mL with age-specific Hgb cutoffs

When to consult moduleConsult the Coverage Criteria section for the precise numeric thresholds that govern initiation and reauthorization decisions

Prior authorization and coding

Ensure correct product-specific coding and that claims reflect the appropriate HCPCS/administration code for the specific agent administered. Follow the member's benefit booklet for coverage determinations and consult the product's FDA dosing/administration information when prescribing and billing.

J1437 – Injection, ferric derisomaltose (Monoferric) 10 mg
J1439 – Injection, ferric carboxymaltose (Injectafer) 1 mg
Q0138 – Injection, ferumoxytol (Feraheme) 1 mg (non-ESRD use)
Q0139 – Injection, ferumoxytol (Feraheme) 1 mg (ESRD on dialysis)

Denial Risk

Benefit/contract limitation

Coverage is subject to the member's benefit contract. Services may be denied if the member's benefit does not include coverage for the requested drug, if exclusions apply, or if the requested service is considered investigational for the indication billed.

Verify member benefits and any plan-specific medical or pharmacy limits prior to authorization
Denied when member contract does not cover the requested drug or indication
Investigational uses (non-FDA approved or combinations not supported by policy) are not covered

Documentation Required

Required medical record documentation

The individual's medical record must document that medical necessity criteria are met. Submit office visit notes that include diagnosis, relevant history, physical evaluation, and medication history. For re-authorization, include objective documentation of clinical response (e.g., hemoglobin change) and pertinent laboratory results.

Office visit notes with diagnosis, history, physical exam, and medication history
Documentation of intolerance to or inadequate response to oral iron (after ≥ 3 months) when required
For CKD or other conditions, documentation of prior use or intolerance to preferred IV iron products when applicable
Laboratory results showing hemoglobin and iron indices; for re-authorization, evidence of clinical response (hemoglobin ↑ ≥ 1 g/dL from baseline) and need for continued therapy

Step Therapy

Step therapy / product sequencing

Step therapy and product sequencing requirements apply as described in the coverage criteria: members must generally demonstrate intolerance to or an inadequate response to oral iron after at least 3 months, or to at least 1 preferred IV iron product (ferrlecit, generic sodium ferric gluconate, INFeD, or Venofer) where specified, before certain agents are authorized. Exceptions include pregnancy or conditions preventing oral iron absorption.

Oral iron trial: ≥ 3 months unless exception (pregnancy or malabsorption)
If required by product criteria, trial of at least 1 preferred IV iron product (Ferrlecit, generic sodium ferric gluconate, INFeD, Venofer) demonstrating intolerance or inadequate response prior to approval of some agents
Product-specific exceptions (e.g., pregnancy, CKD, heart failure) documented in the medical record

Denial Risk

Insufficient documentation

Insufficient documentation may result in denial. If submitted records do not demonstrate the required trials, clinical response, laboratory values, or that the request is within the member's benefit, authorization will be at risk.

Denial risk when records lack documentation of prior oral or IV iron trials when required
Denial risk when laboratory results or evidence of clinical response are not provided for re-authorization
Always include product name, dose, administration date, and indication in documentation

Note

Documentation and prescribing information

Follow FDA-approved dosing and administration for each product. Consult the member's benefit booklet for any additional coverage rules or limitations and for guidance on formulary exceptions and duration of approval.

Prescribe and administer per product's FDA labeling
Check formulary status and submit non-formulary exception requests when appropriate
Non-formulary exception approvals may extend up to 12 months

Selection considerationsChoose product based on indication, number of infusions required, safety profile, and FDA dosing/administration information

GFR stages summary (G1–G5)

G1GFR ≥ 90 mL/min/1.73 m2 — Normal or high

G2GFR 60–89 mL/min/1.73 m2 — Mildly decreased

G3aGFR 45–59 mL/min/1.73 m2 — Mildly to moderately decreased

G3bGFR 30–44 mL/min/1.73 m2 — Moderately to severely decreased

G4GFR 15–29 mL/min/1.73 m2 — Severely decreased

G5GFR < 15 mL/min/1.73 m2 — Kidney failure